Back to search results

MK-1403 for Type 2 Diabetes Mellitus

This study is testing a new medicine called MK-1403, combined with an additive coformulation, for people with Type 2 Diabetes Mellitus. The main goal is to see if MK-1403 is safe and well-tolerated. Researchers will also study how your body handles MK-1403 over time and if it affects a protein called high-sensitivity C-reactive protein (hsCRP) in your blood. You might be able to join if you are 18-75 years old, have Type 2 Diabetes, and a BMI between 18 and 40. The study is looking for 52 participants, but its current status is unclear.

Study design
This study is an interventional trial, meaning you will receive either MK-1403 plus an additive coformulation or a placebo (an inactive substance) plus an additive coformulation. It aims to enroll 52 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track adverse events for up to approximately 28 days and discontinuations due to adverse events for up to approximately 14 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07242469

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

Active, Not Recruiting
PHASE1Ages 18–75InterventionalTreatment
Merck Sharp & Dohme LLC
~52 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:MK-1403 + additive coformulationPlacebo + additive coformulation

At a glance

Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants who experience one or more adverse events (AE)
Measured over Up to approximately 28 days
+1 more outcome measured

Conditions

Diabetes Mellitus, Type 2

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

5 sites across 3 states
California2
Florida2
Missouri1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM)
Has body mass index (BMI) between 18 and 40 kg/m\^2, inclusive

Exclusion

Has Type 1 diabetes mellitus or secondary types of diabetes
Has a history of congestive heart failure (New York Heart Association \[NYHA\] Class 3 or 4)
Has history of myocardial infarction, uncontrolled arrhythmias, cardiac revascularization, angina, unstable peripheral arterial disease and/or stroke
Has history of cancer (malignancy)
Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or human immunodeficiency virus (HIV)
Has a history of gastrointestinal (GI) disease which might affect food and drug absorption, or has had gastric bypass or similar surgery

What this trial measures

  • Number of participants who experience one or more adverse events (AE)Up to approximately 28 days

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported.

  • Number of participants who discontinue study intervention due to adverse eventsUp to approximately 14 days

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.